Register to receive a free US Market Report Suite for Vascular Access Devices and Accessories report synopsis and brochure

According to a new series of reports on the vascular access device and accessories market by iData Research, implantable ports are most commonly inserted in patients undergoing chemotherapy. Growth in the volume of chemotherapy patients in the U.S. will drive growth in the volume of port insertions. Single-lumen ports are expected to continue to be used in the majority of insertion procedures. However, a recent shift in physician preference is expected to increase the share of insertions performed using ports featuring plastic construction and power-injection. The U.S. market for implantable ports comprises conventional implantable ports, power-injectable implantable ports and valved implantable ports.

The largest segment in the total U.S. implantable port market is the power-injectable implantable port segment as they are expected to become the standard of care in the United States. Their prices have been rapidly decreasing in the past few years, dropping to a level comparable to conventional implantable ports in the past. Implantable ports are used more frequently because they offer greater patient comfort, a lower risk of infection and easier long-term vascular access than peripheral inserted central catheters (PICCs) and central venous catheters (CVCs).

“Price declines will be driven by competitive and economic price pressures, bulk purchases by group purchasing organizations (GPOs) and the shift towards less expensive plastic implantable ports,” explains Dr. Kamran Zamanian, CEO of iData. “However, price declines will be moderated by the shift towards premium-priced power-injectable ports.”

The total U.S. market for power-injectable implantable ports comprises single- and double-lumen power-injectable implantable ports. Double-lumen power-injectable implantable ports command significant price premiums over single-lumen power-injectable implantable ports as a greater share of double-lumen power-injectable implantable ports are titanium.

C.R. Bard leads the U.S. market for implantable ports with their line of PowerPort® products. The company sells plastic, titanium, single- and double-lumen ports, as well as power-injectable and non-power-injectable ports. Bard faced strong competition and price pressure in 2015. Pricing pressure was driven in part by the signing of new GPO contracts in early 2014. The company reported a 3% decline in consolidated net sales of ports in 2015 compared to the previous year.

AngioDynamics maintains about 20% of the total U.S. implantable port market through sales of the Xcela® Plus, BioFlo®, Smart Port®, Vortex®, LifePort®, TitanPort®, and Triumph-1® devices. The Xcela® Plus implantable port comes with or without pressure activated safety valve (PASV®) technology and has a larger septum design than conventional ports to facilitate easier access. The PASV® technology sells at a premium and is the only valved catheter technology on the market. In 2013, AngioDynamics received FDA approval for its BioFlo® implantable port product series. BioFlo® technology has been a significant driver of growth for AngioDynamics in recent years and as of January 2016 represented 41% of AngioDynamics’ total vascular access sales. Additional competitors in the U.S. implantable port market include Smiths Medical, Medcomp, Cook Medical, B. Braun, PFM Medical and Teleflex among others.

For Further Information
More on the implantable port market can be found in a series of reports published by iData Research entitled the US Market Report Suite for Vascular Access Devices and Accessories. The suite covers market reports on implantable ports, port needles, central venous catheters, peripherally inserted central catheters, peripheral intravenous catheters, dialysis catheters, ultrasound vascular access device and accessories, syringes and needles.

The iData report series on vascular access devices covers the United States, Japan, South Korea, Australia, India, China, Brazil and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, competitor SWOT analyses, disease overviews, product pipelines, press releases, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more on vascular access device and accessories market data or procedure data, register online or email us at [email protected] for a US Market Report Suite for Vascular Access Devices and Accessories brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.

Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch